All In Biotech

Drug Trial Radar · NCT01916382

Suitability of Nitisinone in Alkaptonuria 2

An International, Multicentre, Randomised, Evaluator-blind, No-treatment Controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Nitisinone in Patients With Alkaptonuria After 12 Months of Treatment, Followed by an Additional 36 Month Treatment Period.

Last checked: Nov 19, 2026Latest source record: May 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

140

Planned (sponsor's estimate)

Start

Apr 2014

Primary completion

Feb 2016

Study completion Feb 2, 2020

Sponsor

Lead sponsor
University of LiverpoolAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a proposal to develop the orphan designated drug, nitisinone, for the treatment of a rare Mendelian disease, Alkaptonuria (AKU). Thanks to our existing successful fundamental and clinical research (cell models, animal models, natural history studies), we are now ready for this final stage of clinical development of nitisinone for AKU: a phase 3 clinical trial to prove efficacy. The results of DevelopAKUre will allow us to make the case to the European Medicines Agency for marketing authorisation of nitisinone for AKU, thereby contributing to the goal of the International Rare Diseases Research Consortium of developing 200 new therapies by 2020.

Conditions

  • Alkaptonuria

Interventions

  • NitisinoneDrug

    drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24 houre Urine Homogentisic acidTime frame: year 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Royal Liverpool Hospital

    Liverpool, Merseyside, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.